Melanoma has traditionally been considered an immunogenic tumor. A number of approaches have been studied for enhancement of antitumor immunity. The first cytokine approved for the treatment of metastatic melanoma, interleukin‐2, has resulted in prolonged responses in a small subset of patients, providing hope that immunotherapy might be useful for this disease. Ipilimumab, a monoclonal antibody to CTLA‐4, was recently approved and a number of other promising investigational approaches are currently being pursued. This manuscript discusses more recent advances in the treatment of melanoma employing a variety of immune‐enhancing approaches. J. Cell. Biochem. 113: 725–734, 2012. © 2011 Wiley Periodicals, Inc.
/lp/wiley/immunotherapy-for-metastatic-melanoma-Z72LtEj4wa